Achieving faster product launch

ISPOR 2016 Achieving faster product launch


How do you obtain non-reimbursed pharmaceutical prices across Europe?

Approximately one in four prescription-only medicinal products are paid out of pocket by EU patients, whereas the rest is funded by the healthcare system or compulsory health insurances via reimbursement procedures. For reimbursed products, the price setting process for new pharmaceutical products are clearly defined across EU markets with information being readily accessible.

There is a lack of published information concerning the pricing processes for non-reimbursed prescription-only medicinal products, therefore, the objective of this research was to determine the national price submission procedures across Europe required for launch and patient access for non-reimbursed prescription-only medicinal products.

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.